Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
In this study, we aim to evaluate the efficacy and safety of an individualized dosing
schedule comprising Aflibercept and RF-PDT in patients with polypoidal choroidal vasculopathy
(PCV). The objective is to compare the visual improvement from baseline to month 12, in eyes
with PCV treated with Aflibercept monotherapy versus combination of Aflibercept with reduced
fluence photodynamic therapy (RF-PDT)
Phase:
N/A
Details
Lead Sponsor:
Singapore National Eye Centre
Collaborators:
National University Hospital, Singapore Tan Tock Seng Hospital